About P2X purinoceptor 5
P2X purinoceptor 5 (P2RX5) is a protein
from Homo sapiens identified by UniProt accession
Q93086, 444 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | P2X purinoceptor 5 |
|---|
| UniProt accession | Q93086 |
|---|
| Gene | P2RX5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 444 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (37)
Diseases linked to this target (Open Targets).
- coronary artery disease · score 0.15
- inflammatory bowel disease · score 0.14
- genetic disorder · score 0.12
- cutaneous melanoma · score 0.10
- Benign familial chorea · score 0.06
- chorea · score 0.04
- X-Linked Combined Immunodeficiency Diseases · score 0.03
- severe combined immunodeficiency due to IKK2 deficiency · score 0.03
- osteosarcoma · score 0.03
- glioblastoma multiforme · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q93086-F1 | alphafold | PREDICTED | 81.55 | — |
Amino-acid sequence (444 residues)
MGQAGCKGLC LSLFDYKTEK YVIAKNKKVG LLYRLLQASI LAYLVVWVFL IKKGYQDVDT SLQSAVITKV KGVAFTNTSD LGQRIWDVAD YVIPAQGENV FFVVTNLIVT PNQRQNVCAE NEGIPDGACS KDSDCHAGEA VTAGNGVKTG RCLRRENLAR GTCEIFAWCP LETSSRPEEP FLKEAEDFTI FIKNHIRFPK FNFSKSNVMD VKDRSFLKSC HFGPKNHYCP IFRLGSVIRW AGSDFQDIAL EGGVIGINIE WNCDLDKAAS ECHPHYSFSR LDNKLSKSVS SGYNFRFARY YRDAAGVEFR TLMKAYGIRF DVMVNGKAGK FSIIPTIINV GSGVALMGAG AFFCDLVLIY LIKKREFYRD KKYEEVRGLE DSSQEAEDEA SGLGLSEQLT SGPGLLGMPE QQELQEPPEA KRGSSSQKGN GSVCPQLLEP HRST
Explore P2X purinoceptor 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets